Below are the top 10 Biotech stocks with highest upside potential, based on the
difference between current price and Wall Street analysts average target price.
One Chinese company (CPHI) is on the list. Bionovo Inc. (NASDAQ:BNVI) has the
1st highest upside potential in this segment of the market. Its upside is
825.8%. Its consensus target price is $5.00 based on the average of all
estimates. Palatin Technologies, Inc. (AMEX:PTN) has the 2nd highest upside
potential in this segment of the market. Its upside is 694.9%. Its consensus
target price is $5.00 based on the average of all estimates. Peregrine
Pharmaceuticals (NASDAQ:PPHM) has the 3rd highest upside potential in this
segment of the market. Its upside is 612.5%. Its consensus target price is $7.13
based on the average of all estimates. Galena Biopharma Inc (NASDAQ:GALE) has
the 4th highest upside potential in this segment of the market. Its upside is
517.3%. Its consensus target price is $4.50 based on the average of all
estimates. Neostem Inc. (AMEX:NBS) has the 5th highest upside potential in this
segment of the market. Its upside is 473.7%. Its consensus target price is $3.56
based on the average of all estimates. CEL-SCI Corporation (AMEX:CVM) has the
6th highest upside potential in this segment of the market. Its upside is
455.6%. Its consensus target price is $2.00 based on the average of all
estimates. Tengion, Inc. (NASDAQ:TNGN) has the 7th highest upside potential in
this segment of the market. Its upside is 440.8%. Its consensus target price is
$2.65 based on the average of all estimates. Sunesis Pharmaceuticals, Inc.
(NASDAQ:SNSS) has the 8th highest upside potential in this segment of the
market. Its upside is 415.3%. Its consensus target price is $6.75 based on the
average of all estimates. China Pharma Holdings, Inc. (AMEX:CPHI) has the 9th
highest upside potential in this segment of the market. Its upside is 405.6%.
Its consensus target price is $4.50 based on the average of all estimates. Idera
Pharmaceuticals, Inc. (NASDAQ:IDRA) has the 10th highest upside potential in
this segment of the market. Its upside is 374.7%. Its consensus target price is
$7.50 based on the average of all estimates.
No comments:
Post a Comment